Molecular Oncology
Volume 1, Issue 2 , Pages 160-171 , September 2007

Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer

  • Bjørn Naume

      Affiliations

    • Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Xi Zhao

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Marit Synnestvedt

      Affiliations

    • Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Elin Borgen

      Affiliations

    • Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Hege Giercksky Russnes

      Affiliations

    • Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Ole Christian Lingjærde

      Affiliations

    • Institute for Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway
    • ,
  • Maria Strømberg

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Gro Wiedswang

      Affiliations

    • Department of Surgery, Ullevål University Hospital, Oslo, Norway
    • ,
  • Gunnar Kvalheim

      Affiliations

    • Laboratory for Cellular Therapy, Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • ,
  • Rolf Kåresen

      Affiliations

    • Department of Surgery, Ullevål University Hospital, Oslo, Norway
    • ,
  • Jahn M. Nesland

      Affiliations

    • Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Norway
    • ,
  • Anne-Lise Børresen-Dale

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Norway
    • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway
    • Institute for Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway
    • Corresponding Author InformationCorresponding author. Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway. Tel.: +47 22934718; Fax: +47 22934440.

Received 13 February 2007 ,Revised 23 March 2007 ,Accepted 26 March 2007.

References 

  1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996;2:811–814
  2. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003;100:3983–3988
  3. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004;64:8534–8540
  4. Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganas M, et al Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann. Oncol. 2005;16:743–748
  5. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 2004;22:2284–2293
  6. Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823
  7. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, et al Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65:2170–2178
  8. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad Ø, et al Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy. 1999;1:377–388
  9. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000;342:525–533
  10. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005;353:793–802
  11. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U.S.A. 2005;102:3738–3743
  12. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–369
  13. Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol. Pathol. 2003;56:275–279
  14. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 2004;10:6622–6628
  15. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, et al The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J. Biol. Chem. 2000;275:32649–32657
  16. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005;65:4059–4066
  17. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, et al SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 2003;31:219–223
  18. Diel IJ, Kaufmann M, Costa SD, Holle R, von MG, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 1996;88:1652–1658
  19. Ein-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics. 2005;21:171–178
  20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 1998;95:14863–14868
  21. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001;61:2505–2512
  22. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J. Clin. Oncol. 2001;19:960–971
  23. Hino S, Kishida S, Michiue T, Fukui A, Sakamoto I, Takada S, et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol. Cell Biol. 2001;21:330–342
  24. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, et al beta2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006;66:9108–9116
  25. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst. 2004;96:956–965
  26. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol. 1995;9:794–804
  27. Kikuchi M, Hatano N, Yokota S, Shimozawa N, Imanaka T, Taniguchi H. Proteomic analysis of rat liver peroxisome: presence of peroxisome-specific isozyme of Lon protease. J. Biol. Chem. 2004;279:421–428
  28. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 2003;100:5974–5979
  29. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354:197–202
  30. Naume B, Borgen E, Kvalheim G, Karesen R, Qvist H, Sauer T, et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin. Cancer. Res. 2001;7:4122–4129
  31. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002;19:607–614
  32. Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. Clin. Cancer Res. 2006;12:7209–7214
  33. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003;33:49–54
  34. Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br. J. Cancer. 2005;93:939–945
  35. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol. Biol. 2004;291:207–216
  36. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10869–10874
  37. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003;100:8418–8423
  38. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127
  39. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 2003;100:10393–10398
  40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005;102:15545–15550
  41. Tan PK, Downey TJ, Spitznagel EL, Xu P, Fu D, Dimitrov DS, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 2003;31:5676–5684
  42. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987;47:6126–6133
  43. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001;98:5116–5121
  44. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  45. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, et al Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004;64:64–71
  46. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. U.S.A. 2003;100:15901–15905
  47. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, et al Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 2003;21:3469–3478
  48. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 2006;98:472–482
  49. Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003;63:5679–5684
  50. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin. Cancer Res. 2004;10:5508–5517
  51. Zhao H, Hastie T, Whitfield ML, Borresen-Dale AL, Jeffrey SS. Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics. 2002;3:31

PII: S1574-7891(07)00014-2

doi: 10.1016/j.molonc.2007.03.004

Molecular Oncology
Volume 1, Issue 2 , Pages 160-171 , September 2007

Article Tools

* Image Usage & Resolution